Peder Fode1, Marc Stegger, Paal Skytt Andersen. 1. Laboratory of Microbial Pathogenesis and Host Susceptibility, Department of Microbiological Surveillance and Research, Statens Serum Institut, 5 Artillerivej DK-2300 Copenhagen S, Denmark.
Abstract
OBJECTIVE: The DEFB103 gene encodes human β-defensin 3, which has a high activity against Staphylococcus aureus. In the general population 20% are persistent nasal carriers of S. aureus, which is a problem for their general health. DEFB103 shows extensive variation in copy number. Copy number variations (CNVs) are believed to play a role in susceptibility to certain diseases. The possible associations between CNVs, mRNA, and nasal S. aureus carriage status were investigated. METHODS: We used the pyrosequencing-based paralog ratio test to determine the DEFB103 copy number. Nasal swabs were collected for RNA and S. aureus determination. S. aureus genotypes were determined by spa typing, and real-time PCR was used to determine DEFB103 mRNA expression. RESULTS: The DEFB103 CNV varied from 2 to 8 copies per diploid genome. No significant difference in copy number was observed among the groups. We found 74% of the volunteers to be non-carriers, 20% to be persistent carriers, and 6% to be intermittent carriers. The S. aureus isolates linked to more than 16 clonal lineages. mRNA expression varied extensively, but no significant differences were observed between the groups. We did not find a linear correlation between CNV and mRNA expression. CONCLUSIONS: The results indicate that DEFB103 CNV does not influence S. aureus carrier status.
OBJECTIVE: The DEFB103 gene encodes human β-defensin 3, which has a high activity against Staphylococcus aureus. In the general population 20% are persistent nasal carriers of S. aureus, which is a problem for their general health. DEFB103 shows extensive variation in copy number. Copy number variations (CNVs) are believed to play a role in susceptibility to certain diseases. The possible associations between CNVs, mRNA, and nasal S. aureus carriage status were investigated. METHODS: We used the pyrosequencing-based paralog ratio test to determine the DEFB103 copy number. Nasal swabs were collected for RNA and S. aureus determination. S. aureus genotypes were determined by spa typing, and real-time PCR was used to determine DEFB103 mRNA expression. RESULTS: The DEFB103 CNV varied from 2 to 8 copies per diploid genome. No significant difference in copy number was observed among the groups. We found 74% of the volunteers to be non-carriers, 20% to be persistent carriers, and 6% to be intermittent carriers. The S. aureus isolates linked to more than 16 clonal lineages. mRNA expression varied extensively, but no significant differences were observed between the groups. We did not find a linear correlation between CNV and mRNA expression. CONCLUSIONS: The results indicate that DEFB103 CNV does not influence S. aureus carrier status.
Authors: Nathan K Archer; Nithin D Adappa; James N Palmer; Noam A Cohen; Jan M Harro; Steven K Lee; Lloyd S Miller; Mark E Shirtliff Journal: Infect Immun Date: 2016-11-18 Impact factor: 3.441
Authors: Caroline Mitchell; Michelle L Gottsch; Congzhou Liu; David N Fredricks; Deborah B Nelson Journal: Am J Obstet Gynecol Date: 2012-11-19 Impact factor: 8.661
Authors: Colin D Veal; Hang Xu; Katherine Reekie; Robert Free; Robert J Hardwick; David McVey; Anthony J Brookes; Edward J Hollox; Christopher J Talbot Journal: Bioinformatics Date: 2013-06-06 Impact factor: 6.937
Authors: Olga Scudiero; Mariarita Brancaccio; Cristina Mennitti; Sonia Laneri; Barbara Lombardo; Margherita G De Biasi; Eliana De Gregorio; Chiara Pagliuca; Roberta Colicchio; Paola Salvatore; Raffaela Pero Journal: Antibiotics (Basel) Date: 2020-04-21